[{"data":1,"prerenderedAt":14},["ShallowReactive",2],{"blog-what-is-signal-intelligence":3},{"category":4,"content":5,"date":6,"description":7,"faq":8,"ogTitle":9,"readTime":10,"slug":11,"tags":12,"title":9},"Signal Intelligence","\u003Ch2 class=\"text-3xl font-bold mb-6\">Beyond Single-Domain Intelligence\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Traditional intelligence approaches tend to focus on a single domain — regulatory\n              monitoring, competitive analysis, or market research — operating in isolation. Signal\n              Intelligence breaks down these silos. It recognizes that the most valuable insights\n              emerge at the intersection of domains: a competitor's FDA clearance combined with a\n              recent Series B funding round tells a more complete story than either signal alone.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform ingests and correlates signals across four domains simultaneously,\n              building unified company profiles that reveal the full picture of market activity. A\n              clinical trial start in one domain becomes a competitive alert in another; a patent\n              filing connects to a potential partnership opportunity; a funding announcement signals\n              market expansion readiness. This cross-domain intelligence is what separates raw data\n              from genuine strategic advantage.\n            \u003C\u002Fp>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">The Four Domains of Signal Intelligence\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Signal intelligence operates across four interconnected domains, each providing a\n              unique window into market activity:\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-primary-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Regulatory Signal Intelligence\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  The systematic monitoring of global health authorities for new clearances,\n                  approvals, certifications, recalls, and regulatory changes. This is the\n                  foundational domain — regulatory signals are the most structured, high-confidence\n                  indicators of market activity.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Key sources:\u003C\u002Fstrong> FDA 510(k) clearances and PMA approvals, EUDAMED NB\n                  certificates, ANVISA registrations, NMPA device approvals, PMDA Shonin\n                  certificates, Health Canada MDEL licenses, TGA ARTG listings, WHO\n                  Prequalification, CDSCO registrations, MFDS certifications.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-accent-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Competitive Signal Intelligence\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Tracking competitor activity through product launches, patent filings, strategic\n                  partnerships, market entries, and organizational changes. Competitive signals\n                  provide context around who is moving, where they are investing, and what markets\n                  they are targeting.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Key sources:\u003C\u002Fstrong> USPTO, EPO, WIPO, CNIPA, KIPO, and JPO patent\n                  filings; SEC EDGAR disclosures (10-K, 8-K, S-1); press releases and corporate\n                  announcements; clinical trial registrations as R&D indicators.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-emerald-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Clinical Signal Intelligence\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Monitoring clinical trial activity, investigator networks, study results, and\n                  scientific publications. Clinical signals are leading indicators of product\n                  development progress — a trial start today signals a regulatory submission\n                  tomorrow and a market entry the year after.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Key sources:\u003C\u002Fstrong> ClinicalTrials.gov registrations and results, EU\n                  CTIS trial authorizations, PubMed biomedical literature, DRKS and other national\n                  trial registries, investigator and site activation data.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6 border-l-4 border-violet-500\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Market Signal Intelligence\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-3\">\n                  Tracking funding rounds, M&A activity, market expansion announcements, partnership\n                  deals, and economic indicators. Market signals reveal financial health, growth\n                  trajectory, and strategic direction — the business context that makes regulatory\n                  and clinical signals actionable.\n                \u003C\u002Fp>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  \u003Cstrong>Key sources:\u003C\u002Fstrong> Crunchbase funding data, Grants.gov SBIR\u002FSTTR\n                  awards, NIH grant funding, SEC filings for public companies, industry press and\n                  news feeds.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">How Signals Flow Across Domains\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The power of Signal Intelligence lies not in any single domain but in the connections\n              between them. A single company generates signals across all four domains\n              simultaneously, and the CI Platform's entity resolution engine links them into a\n              unified intelligence profile:\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-primary-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  1\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Signal Detection\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Our crawlers monitor all global public sources around the clock. When an FDA clearance\n                    is published, a clinical trial starts enrolling, a patent is granted, or a\n                    funding round closes, the signal is ingested within hours.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-accent-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  2\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Cross-Domain Correlation\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Each signal is linked to its source company using entity resolution. The same\n                    company tracked across FDA filings, patent grants, clinical trials, and funding\n                    data builds a unified profile — a single view of that company's complete market\n                    activity.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-primary-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  3\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Classification & Scoring\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Signals are classified by domain, type, source country, and relevance. Our\n                    scoring engine evaluates signal density — a company with regulatory approvals in\n                    multiple geographies, active trials, recent patent filings, and fresh funding\n                    scores as a higher-priority intelligence target.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-accent-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  4\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Company Enrichment\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Each company is enriched with firmographic data: headcount, revenue range,\n                    technology focus, regulatory history across all tracked jurisdictions, clinical\n                    trial history, patent portfolio, funding history, and key decision-makers.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"flex gap-6\">\n                \u003Cdiv\n                  class=\"flex-shrink-0 w-12 h-12 bg-primary-600 text-white rounded-full flex items-center justify-center font-bold text-xl\"\n                >\n                  5\n                \u003C\u002Fdiv>\n                \u003Cdiv>\n                  \u003Ch3 class=\"text-xl font-bold mb-2\">Intelligence Delivery\u003C\u002Fh3>\n                  \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                    Cross-domain intelligence is delivered through customizable alerts, dashboards,\n                    and API feeds. Users can monitor competitors across all four domains, generate\n                    qualified leads from multi-signal triggers, or receive early warnings of market\n                    shifts before they become public knowledge.\n                  \u003C\u002Fp>\n                \u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">24 Data Sources Across Four Domains\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The CI Platform ingests data from 24 carefully curated data sources spanning\n              regulatory agencies, patent offices, clinical trial registries, and market databases\n              worldwide:\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"grid md:grid-cols-2 gap-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Regulatory (10 sources)\u003C\u002Fh3>\n                \u003Cul class=\"space-y-2 dark:text-slate-400\">\n                  \u003Cli>• FDA (USA) — 510(k) clearances, PMA approvals, recalls\u003C\u002Fli>\n                  \u003Cli>• EUDAMED (EU) — NB certificates, IVDR decisions\u003C\u002Fli>\n                  \u003Cli>• ANVISA (Brazil) — device registrations\u003C\u002Fli>\n                  \u003Cli>• NMPA (China) — device and product registrations\u003C\u002Fli>\n                  \u003Cli>• PMDA (Japan) — medical device approvals\u003C\u002Fli>\n                  \u003Cli>• Health Canada — MDL\u002FMDEL licenses\u003C\u002Fli>\n                  \u003Cli>• MFDS (South Korea) — device certifications\u003C\u002Fli>\n                  \u003Cli>• CDSCO (India) — device registrations\u003C\u002Fli>\n                  \u003Cli>• TGA (Australia) — ARTG listings\u003C\u002Fli>\n                  \u003Cli>• WHO Prequalification — global health products\u003C\u002Fli>\n                \u003C\u002Ful>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Patent (6 sources)\u003C\u002Fh3>\n                \u003Cul class=\"space-y-2 dark:text-slate-400\">\n                  \u003Cli>• USPTO (USA) — granted patents and applications\u003C\u002Fli>\n                  \u003Cli>• EPO (Europe) — European patent grants\u003C\u002Fli>\n                  \u003Cli>• WIPO (Global) — PCT international applications\u003C\u002Fli>\n                  \u003Cli>• CNIPA (China) — Chinese patent filings\u003C\u002Fli>\n                  \u003Cli>• KIPO (South Korea) — Korean patent filings\u003C\u002Fli>\n                  \u003Cli>• JPO (Japan) — Japanese patent filings\u003C\u002Fli>\n                \u003C\u002Ful>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Clinical (4 sources)\u003C\u002Fh3>\n                \u003Cul class=\"space-y-2 dark:text-slate-400\">\n                  \u003Cli>• ClinicalTrials.gov — 450K+ registered studies\u003C\u002Fli>\n                  \u003Cli>• EU CTIS — EU clinical trial authorizations\u003C\u002Fli>\n                  \u003Cli>• PubMed — biomedical literature\u003C\u002Fli>\n                  \u003Cli>• DRKS — German clinical trials register\u003C\u002Fli>\n                \u003C\u002Ful>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Market (4 sources)\u003C\u002Fh3>\n                \u003Cul class=\"space-y-2 dark:text-slate-400\">\n                  \u003Cli>• Crunchbase — funding rounds and M&A data\u003C\u002Fli>\n                  \u003Cli>• SEC EDGAR — public company disclosures\u003C\u002Fli>\n                  \u003Cli>• Grants.gov — SBIR\u002FSTTR and NIH awards\u003C\u002Fli>\n                  \u003Cli>• Industry news feeds — press releases and announcements\u003C\u002Fli>\n                \u003C\u002Ful>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Each source runs on its own crawl schedule — from daily for high-volume regulatory and\n              clinical sources to weekly for patent databases and market feeds. The platform\n              processes over 15,000 signals per day with an average detection latency of under 12\n              hours from source publication.\n            \u003C\u002Fp>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">From Signal to Intelligence\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Detection is only the first step. The real value of Signal Intelligence lies in the\n              pipeline that transforms raw cross-domain signals into actionable business outcomes:\n            \u003C\u002Fp>\n\n            \u003Cdiv class=\"space-y-6 my-8\">\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Competitive Monitoring\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Track competitors across all four domains simultaneously. See when a competitor\n                  receives FDA clearance, files a patent in a new technology area, starts a clinical\n                  trial, or raises funding — and understand how these signals combine to reveal\n                  strategic direction.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Lead Generation\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Identify companies with high signal density across regulatory, clinical, and\n                  market domains. A company that received recent regulatory approvals, has active\n                  clinical trials, and raised a Series A represents a validated, well-funded\n                  prospect ready for partnership or solution outreach.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Partner Scouting\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Find CDMOs, contract manufacturers, and technology partners with the right\n                  regulatory footprint, patent portfolio, and clinical expertise. Cross-domain\n                  signal intelligence reveals capability depth that no single domain can provide.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Market Expansion Planning\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Identify companies expanding into new geographic markets by monitoring regulatory\n                  activity across jurisdictions. Cross-reference with funding data to assess\n                  expansion readiness and with patent filings to understand technology positioning\n                  in each market.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n              \u003Cdiv class=\"card bg-slate-50 dark:bg-slate-800 p-6\">\n                \u003Ch3 class=\"text-xl font-bold mb-3\">Clinical Partnership Targeting\u003C\u002Fh3>\n                \u003Cp class=\"text-slate-600 dark:text-slate-300\">\n                  Monitor clinical trial activity to identify investigators, sites, and sponsors\n                  active in your therapeutic area. Combine with funding data to prioritize\n                  well-capitalized trials and with patent data to understand the competitive IP\n                  landscape.\n                \u003C\u002Fp>\n              \u003C\u002Fdiv>\n            \u003C\u002Fdiv>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Why Now?\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              The volume of publicly available signal data has exploded. Regulatory agencies\n              worldwide publish more data than ever before. Clinical trial registries have expanded\n              coverage and transparency requirements. Patent data is increasingly digitized and\n              accessible. Funding data platforms provide real-time visibility into private company\n              activity.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Yet most organizations still approach these domains in isolation — a regulatory\n              affairs team monitors FDA while a business development team tracks funding rounds and\n              an R&D team watches clinical trials. The opportunity lies in integration: cross-domain\n              signal intelligence reveals patterns and connections that no single-domain approach\n              can detect.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Companies that invest in cross-domain signal intelligence gain a structural advantage.\n              They see market movements first, identify opportunities before competitors, make\n              faster partnership decisions, and navigate regulatory complexity with the full context\n              of competitive, clinical, and market dynamics.\n            \u003C\u002Fp>\n\n            \u003Ch2 class=\"text-3xl font-bold mb-6 mt-12\">Conclusion\u003C\u002Fh2>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-6 leading-relaxed\">\n              Signal Intelligence represents a new category of business intelligence that cuts\n              across traditional domain boundaries. By combining regulatory, competitive, clinical,\n              and market signals from 24 global data sources, it provides the unified intelligence\n              picture that complex, regulated industries need to compete effectively.\n            \u003C\u002Fp>\n            \u003Cp class=\"text-slate-600 dark:text-slate-400 mb-8 leading-relaxed\">\n              Whether you are monitoring competitors across multiple dimensions, generating\n              qualified leads from cross-domain signal triggers, scouting partners with verified\n              regulatory and clinical footprints, or planning market expansion with the full\n              intelligence picture, the CI Platform delivers the signal intelligence you need — when\n              you need it.\n            \u003C\u002Fp>","2026-01-01","Learn how Signal Intelligence transforms regulatory, competitive, clinical, and market signals from 24 global data sources into unified, actionable business intelligence for regulated industries.",null,"What is Signal Intelligence?",7,"what-is-signal-intelligence",[13],"signal-intelligence",1786979507459]